

BIOVANCE®

Human Amniotic Membrane Allograft

DESCRIPTION

BIOVANCE® is a decellularized, dehydrated human amniotic membrane (DDHAM) with a preserved natural epithelial basement membrane and an intact extracellular matrix structure. The epithelial basement membrane and extracellular matrix of this allograft provide a natural scaffold. BIOVANCE provides a protective cover from the surrounding environment.

INDICATIONS FOR USE

BIOVANCE is an allograft intended for use as a biological membrane covering that provides an extracellular matrix. As a barrier membrane, BIOVANCE is intended to protect the underlying tissue and preserve tissue plane boundaries. Indications include, but are not limited to, surgical covering, wrap or barrier, application to partial- and full-thickness, acute and chronic wounds (such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites; and diabetic, venous, arterial, pressure and other ulcers), including wounds with exposed tendon, muscle, bone or other vital structures.

REGULATORY STATUS

BIOVANCE is minimally manipulated during processing and is regulated by the FDA as a human tissue-based product under Section 361 of the Public Health Service Act when applied for homologous use in the recipient. This product is distributed only to licensed health care practitioners.

QUALITY ASSURANCE

BIOVANCE is produced from human amniotic membrane derived from the placentas of normal, healthy, full-term pregnancies. Each donor has been determined by trained, qualified, and responsible personnel to meet the screening and testing requirements of 21 CFR Part 1271 Subpart C: Donor Eligibility. The record of this determination, including Donor Medical History Record, test results, test methods, and the name and address of the testing laboratories are retained on file for each donor by Celularity Inc. The communicable disease testing was performed by a laboratory certified under the CLIA of 1988 (42 USC 263a) and 42 CFR part 493. Current testing cannot provide absolute assurance that the tissue will not transmit infectious disease to the recipient.

BIOVANCE is tested post-sterilization to demonstrate the absence of bacterial and fungal pathogens.

Testing for endotoxins is conducted to assure levels are below 20 EU/piece. BIOVANCE is non-pyrogenic.

CONTRAINDICATIONS

BIOVANCE is contraindicated in patients with a known hypersensitivity to BIOVANCE.

WARNINGS

If a patient has an adverse reaction related to the use of BIOVANCE, immediately discontinue its use. BIOVANCE should not be used on clinically infected wounds.

PRECAUTIONS

- The pouch contents are sterile if the pouch is unopened and undamaged. Do not use if package seal is broken. Discard material if mishandling has caused possible damage or contamination. Do not resterilize.
- BIOVANCE must be used prior to the expiration date on the product pouch.
- BIOVANCE should not be used together with a collagenase product on the wound.

HOW SUPPLIED

BIOVANCE is supplied in rectangular and disc configurations in a range from 10mm discs to 120 sq cm sheets. Dehydrated sterile sheet in a single-patient, single-use, double-peel pouch. The transparent inner peel pouch and single tissue sheet are supplied sterile and may be placed directly into the sterile field. Included in the packaging with the product pouch are this insert, a Tissue Tracking Letter, and a set of 6 patient labels.

Once opened, allograft must be used immediately or discarded.

STORAGE

Store in a clean, dry environment at ambient room temperature.

STERILIZATION

BIOVANCE is an aseptically processed product and is terminally sterilized with E-beam irradiation.

RECIPIENT TRACKING

The FDA requires a system of record keeping that enables the tracking of human tissue-based products from donor to consignee and vice versa. It is the responsibility of the practitioner to maintain sufficient records to permit prompt identification of the recipient. Tracking labels are enclosed in the BIOVANCE packaging to facilitate this process and should be affixed to the patient medical records. The enclosed Tracking Letter provides more detailed instructions.

INSTRUCTIONS FOR USE

These recommendations are designed to serve only as general guidelines. They are not intended to supersede institutional protocols or professional clinical judgment concerning patient care.

BIOVANCE should not be applied until excessive exudate or bleeding, acute swelling, and infection are controlled.

BIOVANCE should not be applied for structural support.

Each package of BIOVANCE is intended for use on a single patient on one occasion.

Discard any unused portions of BIOVANCE per institutional procedures.

No specific orientation (which side is up or down) of BIOVANCE is required.

- Always handle BIOVANCE using aseptic techniques.
- The inner pouch is sterile and may be placed in the surgical field; however, the outer pouch is not sterile and should be handled accordingly.
- Sterile atraumatic forceps should be used to remove BIOVANCE from its inner peel-pouch.

Instructions for Wound Care

1. Prepare the wound area using standard methods to ensure the wound is free of debris and necrotic tissue; if necessary, debride the wound to ensure the wound edges and base contain viable tissue prior to placement of BIOVANCE.
2. BIOVANCE can be trimmed to the desired shape and size when dry out of the package. If the wound is larger than a single sheet, multiple sheets of BIOVANCE (overlapping edges) may be used to cover the open wound area.
3. Apply BIOVANCE dry and allow wound fluid absorption to hydrate or add sterile saline or other sterile isotonic solution, as needed to hydrate. Smooth the BIOVANCE so that it conforms to the wound surface.
4. The clinician should determine how to anchor BIOVANCE. When suturing, taping or stapling the sheet, ensure that BIOVANCE overlaps adjacent intact skin.
5. If there is a concern about wound fluid collection beneath BIOVANCE, small slits may be made through the allograft to facilitate drainage.
6. After application of BIOVANCE, use an appropriate, nonadherent, secondary dressing to maintain a moist wound environment and the placement of the tissue.
7. Change the secondary dressing as needed to maintain a moist, clean wound area. Wound type, location, size, depth, amount of exudate, and user preference determine the optimal secondary dressing.
8. Do not forcibly remove sections of BIOVANCE that are adhered to the wound. On inspection, if BIOVANCE is no longer covering the wound, or progress has slowed, place an additional piece of BIOVANCE over the wound.
9. Discontinue BIOVANCE treatment upon complete closure of the wound.

Instructions for Surgical Applications

1. Repair the tissue defect using standard surgical methods appropriate for type of repair of tendon, muscle, or other vital structures.
2. BIOVANCE may be trimmed to the desired shape and size. It is best to cut BIOVANCE when it is dry. This may be done while it is still within the inner sterile pouch by cutting through the pouch and the tissue simultaneously.
3. More than one sheet of BIOVANCE may be applied to provide the desired coverage.
4. Place BIOVANCE dry as a surgical covering or wrap to the affected area that requires its barrier function utilizing the clinician's preferred technique. Allow fluid absorption to hydrate or add sterile saline or other sterile isotonic solution, as needed, to hydrate. Smooth the BIOVANCE so that it conforms to the repair.
5. The clinician should determine the need for and method of anchoring BIOVANCE. When suturing or stapling the sheet, ensure that BIOVANCE is in contact with the affected area.
6. After BIOVANCE placement, close the overlying tissue or structure utilizing standard surgical techniques.



Celularity Inc.
170 Park Avenue
Florham Park, NJ 07932

For product information or adverse reaction reporting, telephone 1-844-963-2273

The Health Care Practitioner receiving this human tissue shall have sole discretion and responsibility to determine in accordance with applicable law and professional standards if the tissue is usable and suitable for any and all uses to which the Health Care Practitioner shall apply the tissue, and upon delivery of the human tissue by Celularity Inc. to the Health Care Practitioner and thereafter the Health Care Practitioner accepts and shall have full responsibility and liability with respect to such tissue. ALL HUMAN TISSUE FURNISHED BY CELULARITY INC TO THE HEALTH CARE PRACTITIONER IS PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT OF THIRD PARTY PROPRIETARY RIGHTS UNLESS DISCLAIMING SUCH WARRANTIES IS PROHIBITED BY LAW.

BIOVANCE® is a registered trademark of Celularity Inc.